Hibma JE - Search Results

1

Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children.

Savic RM, Ruslami R, Hibma JE, Hesseling A, Ramachandran G, Ganiem AR, Swaminathan S, McIlleron H, Gupta A, Thakur K, van Crevel R, Aarnoutse R, Dooley KE. Savic RM, et al. Among authors: hibma je. Clin Pharmacol Ther. 2015 Dec;98(6):622-9. doi: 10.1002/cpt.202. Epub 2015 Oct 22. Clin Pharmacol Ther. 2015. PMID: 26260983 Free PMC article.

2

The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.

Hibma JE, Zur AA, Castro RA, Wittwer MB, Keizer RJ, Yee SW, Goswami S, Stocker SL, Zhang X, Huang Y, Brett CM, Savic RM, Giacomini KM. Hibma JE, et al. Clin Pharmacokinet. 2016 Jun;55(6):711-21. doi: 10.1007/s40262-015-0346-3. Clin Pharmacokinet. 2016. PMID: 26597253 Free PMC article. Clinical Trial.

3

Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.

Hibma JE, Radtke KK, Dorman SE, Jindani A, Dooley KE, Weiner M, McIlleron HM, Savic RM. Hibma JE, et al. Am J Respir Crit Care Med. 2020 Sep 15;202(6):866-877. doi: 10.1164/rccm.201912-2489OC. Am J Respir Crit Care Med. 2020. PMID: 32412342 Free PMC article.

4

Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children.

Radtke KK, Hibma JE, Hesseling AC, Savic RM. Radtke KK, et al. Among authors: hibma je. Eur Respir J. 2021 Jan 5;57(1):2001756. doi: 10.1183/13993003.01756-2020. Print 2021 Jan. Eur Respir J. 2021. PMID: 32703775 Free PMC article. No abstract available.

5

Clinical Pharmacology Worldwide: A Global Health Perspective.

Wenning L, Pillai GC, Knepper TC, Ilic K, Ali AM, Hibma JE. Wenning L, et al. Among authors: hibma je. Clin Pharmacol Ther. 2021 Oct;110(4):946-951. doi: 10.1002/cpt.2274. Epub 2021 May 19. Clin Pharmacol Ther. 2021. PMID: 33893656 Review.

6

Pharmacokinetic/Pharmacodynamic Modeling to Support the Re-approval of Gemtuzumab Ozogamicin.

Fostvedt LK, Hibma JE, Masters JC, Vandendries E, Ruiz-Garcia A. Fostvedt LK, et al. Among authors: hibma je. Clin Pharmacol Ther. 2019 Nov;106(5):1006-1017. doi: 10.1002/cpt.1500. Epub 2019 Jul 9. Clin Pharmacol Ther. 2019. PMID: 31070776 Free PMC article.

7

Response to "Lorlatinib Exposed: A Far from Optimal Dose".

Chen J, Ruiz-Garcia A, James LP, Peltz G, Thurm H, Clancy J, Hibma J. Chen J, et al. Clin Pharmacol Ther. 2022 Jun;111(6):1197-1198. doi: 10.1002/cpt.2580. Epub 2022 Mar 31. Clin Pharmacol Ther. 2022. PMID: 35358326 No abstract available.

8

Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia.

Hibma J, Knight B. Hibma J, et al. Clin Pharmacokinet. 2019 Mar;58(3):335-347. doi: 10.1007/s40262-018-0699-5. Clin Pharmacokinet. 2019. PMID: 30062662 Clinical Trial.

9

Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling.

Hibma JE, Kantarjian HM, DeAngelo DJ, Boni JP. Hibma JE, et al. Br J Clin Pharmacol. 2019 Mar;85(3):590-600. doi: 10.1111/bcp.13832. Epub 2019 Jan 21. Br J Clin Pharmacol. 2019. PMID: 30536405 Free PMC article. Clinical Trial.

10

Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib.

Ruiz-Garcia A, Tan W, Li J, Haughey M, Masters J, Hibma J, Lin S. Ruiz-Garcia A, et al. Pharmaceutics. 2020 Apr 7;12(4):330. doi: 10.3390/pharmaceutics12040330. Pharmaceutics. 2020. PMID: 32272733 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15 results

Search Page